Metabolomics diagnostic approach to mustard airway diseases: a preliminary study

Document Type: Original Article

Authors

1 Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran

2 Pulmonary Department, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

3 Department of Basic Sciences, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Chronic Kidney Disease Research Center, Labbafinejad Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

6 Department of Chemistry, Faculty of Sciences, Tarbiat Modares University, Tehran, Iran

7 Physiotherapy Research Center, School of Rehabilitation, Shahid Beheshti University of Medical Sciences, Tehran, Iran

8 Department of Chemistry, Sharif University of Technology, Tehran, Iran

9 Department of Chemistry, Faculty of Science, University of Tehran, Tehran, Iran

Abstract

Objective(s): This study aims to evaluate combined proton nuclear magnetic resonance (1H NMR) spectroscopy and gas chromatography-mass spectrometry (GC-MS) metabolic profiling approaches, for discriminating between mustard airway diseases (MADs) and healthy controls and for providing biochemical information on this disease.
Materials and Methods: In the present study, analysis of serum samples collected from 17 MAD subjects and 12 healthy controls was performed using NMR. Of these subjects, 14 (8 patients and 6 controls) were analyzed by GC-MS. Then, their spectral profiles were subjected to principal component analysis (PCA) and orthogonal partial least squares regression discriminant analysis (OPLS-DA).
Results: A panel of twenty eight metabolite biomarkers was generated for MADs, sixteen  NMR-derived metabolites (3-methyl-2-oxovaleric acid, 3-hydroxyisobutyrate, lactic acid, lysine, glutamic acid, proline, hydroxyproline, dimethylamine, creatine, citrulline, choline, acetic acid, acetoacetate, cholesterol, alanine, and lipid (mainly VLDL)) and twelve GC-MS-derived metabolites (threonine, phenylalanine, citric acid, myristic acid, pentadecanoic acid, tyrosine, arachidonic acid, lactic acid, propionic acid, 3-hydroxybutyric acid, linoleic acid, and oleic acid). This composite biomarker panel could effectively discriminate MAD subjects from healthy controls, achieving an area under receiver operating characteristic curve (AUC) values of 1 and 0.79 for NMR and GC-MS, respectively.
Conclusion: In the present study, a robust panel of twenty-eight biomarkers for detecting MADs was established. This panel is involved in three metabolic pathways including aminoacyl-tRNA biosynthesis, arginine, and proline metabolism, and synthesis and degradation of ketone bodies, and could differentiate MAD subjects from healthy controls with a higher accuracy.

Keywords

Main Subjects


1. Javadi M-A, Yazdani S, Sajjadi H, Jadidi K, Karimian F, Einollahi B, et al. Chronic and delayed-onset mustard gas keratitis: report of 48 patients and review of literature. Ophthalmology 2005; 112:617-625. e612.

2. Spoo JW, Monteiro-Riviere NA, Riviere JE. Detection of sulfur mustard bis (2-chloroethyl) sulfide and metabolites after topical application in the isolated perfused porcine skin flap. Life Sci 1995; 56:1385-1394.

3. Aghanouri R, Ghanei M, Aslani J, Keivani-Amine H, Rastegar F, Karkhane A. Fibrogenic cytokine levels in bronchoalveolar lavage aspirates 15 years after exposure to sulfur mustard. Am J Physiol Lung Cell Mol Physiol 2004; 287:L1160-L1164.

4. Dompeling E, Jöbsis Q, Vandevijver N, Wesseling G, Hendriks H. Chronic bronchiolitis in a 5‐yr-old child after exposure to sulphur mustard gas. Eur Respir J 2004; 23:343-346.

5. Thomason JW, Rice TW, Milstone AP. Bronchiolitis obliterans in a survivor of a chemical weapons attack. JAMA 2003; 290:598-599.

6. Ghanei M, Harandi AA. Long term consequences from exposure to sulfur mustard: a review. ‎Inhal Toxicol 2007; 19:451-456.

7. Aliannejad R, Peyman M, Ghanei M. Noninvasive ventilation in mustard airway diseases. Respir Care 2015; 60:1324-1329.

8. Sahebkar A, Antonelli-Incalzi R, Panahi Y, Ghanei M, Pedone C. Mustard lung and COPD: common features and treatment? Lancet Respir Med 2015; 3:747-748.

9. Brindle JT, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HW, et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics. Nat Med 2002; 8:1439-1445.

10. Srivastava NK, Annarao S, Sinha N. Metabolic status of patients with muscular dystrophy in early phase of the disease: In vitro, high resolution NMR spectroscopy based metabolomics analysis of serum. Life Sci 2016; 151:122-129.

11. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K, et al. Potential metabolite markers of schizophrenia. Mol psychiatry 2013; 18:67-78.

12. Jain M, Nilsson R, Sharma S, Madhusudhan N, Kitami T, Souza AL, et al. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012; 336:1040-1044.

13. Nobakht M. Gh BF, Aliannejad R, Rezaei-Tavirani M, Taheri S, Oskouie AA. The metabolomics of airway diseases, including COPD, asthma and cystic fibrosis. Biomarkers 2014; 20:5-16.

14. Nobakht M. Gh BF, Arefi Oskouie A, Rezaei-Tavirani M, Aliannejad R, Taheri S, Fathi F, et al. NMR spectrometry-based metabolomic study of serum in sulfur mustard exposed patients with lung disease. Biomarkers 2016; 22:413-419.

15. Nobakht BF, Aliannejad R, Rezaei-Tavirani M, Arefi Oskouie A, Naseri MT, Parastar H, et al. NMR-and GC/MS-based metabolomics of sulfur mustard exposed individuals: a pilot study. Biomarkers 2016; 21:479-489.

16. Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013; 187:347-365.

17. Eilers PH. Parametric time warping. Anal Chem 2004; 76:404-411.

18. Skov T, van den Berg F, Tomasi G, Bro R. Automated alignment of chromatographic data. J Chemom 2006; 20:484-497.

19. Tomasi G, van den Berg F, Andersson C. Correlation optimized warping and dynamic time warping as preprocessing methods for chromatographic data. J Chemom 2004; 18:231-241.

20. Nielsen N-PV, Carstensen JM, Smedsgaard J. Aligning of single and multiple wavelength chromatographic profiles for chemometric data analysis using correlation optimised warping. J Chromatogr A 1998; 805:17-35.

21. Nicholson JK, Foxall PJ, Spraul M, Farrant RD, Lindon JC. 750 MHz 1H and 1H-13C NMR spectroscopy of human blood plasma. Anal Chem 1995; 67:793-811.

22. Xu WF, Upur H, Wu YH, Mamtimin B, Yang J, Ga YJ, et al. Metabolomic changes in patients with chronic obstructive pulmonary disease with abnormal Savda syndrome. Exp Ther Med 2015; 9:425-431.

23. Kapoor S, Clay E, Wallace GR, Fitzpatrick M, Bayley R, Young SP. Metabolomics in the analysis of inflammatory diseases: INTECH Open Access Publisher; 2012.

24. White JR, Harris RA, Lee SR, Craigon MH, Binley K, Price T, et al. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 2004; 83:1-8.

25. Albina JE, Henry W, Mastrofrancesco B, Martin B-A, Reichner JS. Macrophage activation by culture in an anoxic environment. J Immunol 1995; 155:4391-4396.

26. Scannell G. Leukocyte responses to hypoxic/ischemic conditions. New horizons (Baltimore, Md) 1996; 4:179-183.

27. Attaran D, Lari SM, Towhidi M, Marallu HG, Ayatollahi H, Khajehdaluee M, et al. Interleukin-6 and airflow limitation in chemical warfare patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010; 5:335-340.

28. Arroyo CM, Broomfield CA, Hackley BE. The role of interleukin-6 (IL-6) in human sulfur mustard (HD) toxicology. Int J Toxicol 2001; 20:281-296.

29. Arroyo C, Schafer R, Kurt E, Broomfield C, Carmichael A. Response of normal human keratinocytes to sulfur mustard (HD): cytokine release using a non-enzymatic detachment procedure. Hum Exp Toxicol 1999; 18:1-11.

30. Nobakht M. Gh BF, Oskouie AA, Aliannejad R, Rezaei-Tavirani M, Tavallaie S, Baghban AA, et al. Pro-oxidant–antioxidant balance in Iranian veterans with sulfur mustard toxicity and different levels of pulmonary disorders. Drug Chem Toxicol 2015:39: 362-366.

31. Tappia PS, Dent MR, Dhalla NS. Oxidative stress and redox regulation of phospholipase D in myocardial disease. Free Radic Biol Med 2006; 41:349-361.

32. Storm C, Danne O, Ueland PM, Leithner C, Hasper D, Schroeder T. Serial plasma choline measurements after cardiac arrest in patients undergoing mild therapeutic hypothermia: a prospective observational pilot trial. PloS One 2013; 8:e76720.

33. Balsinde J, Balboa MA, Insel PA, Dennis EA. Regulation and inhibition of phospholipase A2. Annu Rev Pharmacol Toxicol 1999; 39:175-189.

34. Ray R, Legere R, Majerus B, Petrali J. Sulfur mustard-induced increase in intracellular free calcium level and arachidonic acid release from cell membrane. Toxicol Appl Pharmacol 1995; 131:44-52.

35. Lefkowitz LJ, Smith WJ. Sulfur mustard-induced arachidonic acid release is mediated by phospholipase D in human keratinocytes. Biochem Biophys Res Commun 2002; 295:1062-1067.

36. Sorenson DK, Kelly TM, Murray DK, Nelson DH. Corticosteroids stimulate an increase in phospholipase A2 inhibitor in human serum. J Steroid Biochem 1988; 29:271-273.

37. Kumari S, Tishel R, Eisenbach M, Wolfe AJ. Cloning, characterization, and functional expression of acs, the gene which encodes acetyl coenzyme A synthetase in Escherichia coli. J Bacteriol 1995; 177:2878-2886.

38. Wolfe R, Shaw J, Durkot M. Energy metabolism in trauma and sepsis: the role of fat. Prog Clin Biol Res 1982; 111:89-109.

39. Keshari KR, Zektzer AS, Swanson MG, Majumdar S, Lotz JC, Kurhanewicz J. Characterization of intervertebral disc degeneration by high‐resolution magic angle spinning (HR‐MAS) spectroscopy. Magn Reson Med 2005; 53:519-527.

40. Agin K, Rajaee A, Mehrabi M, Darjani HRJ, Ghofrani H. Osteoporosis among asthmatic patients exposed to mustard gas compared with non-exposed asthmatics. Tanaffos 2004; 3:7-11.

41. Picado C, Luengo M. Corticosteroid-induced bone loss. Drug safety 1996; 15:347-359.

42. Shuster S. Osteoporosis, a unitary hypothesis of collagen loss in skin and bone. Med Hypotheses 2005; 65:426-432.

43. Sorva R, Turpeinen M, Juntunen-Backman K, Karonen S-L, Sorva A. Effects of inhaled budesonide on serum markers of bone metabolism in children with asthma. J Allergy Clin Immunol 1992; 90:808-815.

44. Shahar I, Fireman E, Topilsky M, Grief J, Kivity S, Spirer Z, et al. Effect of IL-6 on alveolar fibroblast proliferation in interstitial lung diseases. Clin Immunol Immunopathol 1996; 79:244-251.

45. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, et al. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92:226-233.

46. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG, NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun 1987; 148:671-677.

47. Pullamsetti SS, Savai R, Dumitrascu R, Dahal BK, Wilhelm J, Konigshoff M, et al. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci Transl Med 2011; 3:87ra53-87ra53.

48. Gao X, Ray R, Xiao Y, Ishida K, Ray P. Macrolide antibiotics improve chemotactic and phagocytic capacity as well as reduce inflammation in sulfur mustard-exposed monocytes. Pulm Pharmacol Ther 2010; 23:97-106.

49. Gao X, Ray R, Xiao Y, Barker PE, Ray P. Inhibition of sulfur mustard-induced cytotoxicity and inflammation by the macrolide antibiotic roxithromycin in human respiratory epithelial cells. BMC Cell Biol 2007; 8:17.
50. Ghanei M, Tazelaar HD, Chilosi M, Harandi AA, Peyman M, Akbari HMH, et al. An international collaborative pathologic study of surgical lung biopsies from mustard gas-exposed patients. Respir Med 2008; 102:825-830.